Safety and Efficacy of Latitud™ Hip Replacement in Total Hip Arthroplasty: An Observational Study in Kazakhstan.

OBJECTIVES

Total hip replacement (THR) is one of the most successful surgical procedures globally for managing end-stage hip osteoarthritis. Latitud™ (Meril Healthcare Pvt. Ltd., Gujarat, India) hip replacement system is at the forefront of restoring mobility and improving patient outcomes. This study aimed to evaluate the safety and effectiveness of the Latitud™ hip replacement in total hip arthroplasty.

METHODS

In this retrospective, single-center, post-market, observational study, patients who underwent THR and were treated in our hospital from 2018 to 2020 were included. The primary outcome was the THR-related intra- and postoperative complications and revision rate at one-year follow-up. Secondary outcomes were other patient-reported outcomes, radiographic analysis, Harris hip score, adverse events, implant dislocation, and implant survivorship rate. Data were collected using a pre-designed data collection form.

RESULTS

A total of 150 patients with a mean age of 53.90 ± 11.44 years were enrolled. The surgical procedures were successful without any major complications. There was a significant (p < 0.001) improvement in the Harris hip score. No death was observed throughout the study. There was one (0.67%) intra-operative fracture, with the patient having a closed comminuted fracture of the upper and middle third of the left femur and anemia. Seven patients (4.67%) required postoperative blood transfusions. During the follow-up period, there was no revision surgery or implant dislocation.

CONCLUSION

This observational study suggests that the Latitud™ hip replacement system was favorable in terms of safety and effective in a real-world setting in Kazakhstan. The study showed promising results in pain alleviation, functional improvement, and implant survivorship.